Objective: Immunochemical detection of the protein p16INK4a in cervical cytology is used in combination with Ki-67. Cells positive for both proteins are certain to have been transformed by high-risk HPV. p16/Ki-67 immunocytochemistry provides a significant improvement in specificity over cytology and HPV DNA testing. However, p16/Ki-67 immunocytochemistry also has its limitations. Study Design: The research is based on the follow-up of 1,131 patients for whom p16/Ki-67 immunocytochemistry was performed with cytology. Dependencies on the age of patients with LSIL, number of p16/Ki-67-positive cells, and different results during repeated examinations were analyzed. Results: In LSIL, positive p16/Ki-67 is less specific for ≥CIN2/HSIL for patients younger than 30 years compared to patients aged 30 years or older (61.1 vs. 75.7%, p < 0.013). Using a score of 10 p16/Ki-67-marked cells as a positive result instead of 1 led to significantly higher specificity (89.0 vs. 70.2%, p < 0.001). This modified threshold offers better risk assessment in LSIL. In repeated immunocytochemical investigations, 28.4% of the results deviated from the first examination. Conclusion: The abovementioned discrepancies can be interpreted as hints about the molecular biological causes of suboptimal performance of p16/Ki-67. An efficient and reliable application of p16/Ki-67 immunocytochemistry requires knowledge of its methodological limitations.

1.
Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P: Molekularbiologie der Zelle, ed 5. Weinheim, Schäfer U, Wiley-VCH Verlag, Germany, 2011.
2.
Reuschenbach M, Vinokura S, von Knebel Doeberitz M: HPV-associated carcinomas of the female genital tract. Molecular mechanisms of development (in German). Pathologe 2011;32:451-460.
3.
Reuschenbach M, Vinokura S, von Knebel Doeberitz M: Etiology of cervical cancer and its precursors (in German). Onkologe 2012;18:9-19.
4.
McLaughlin-Drubin ME, Crum CP, Munger K: Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc Natl Acad Sci USA 2011;108:2130-2135.
5.
Trunk MJ, Wentzensen N, von Knebel Doeberitz M: Molecular pathogenesis of cervical cancer (in German). Pathologe 2005;26:283-290.
6.
Schmidt D, Bergeron CH, Denton KJ, et al: p16/Ki-67 Dual-stain cytology in the triage of ASCUS and LSIL Papanicolaou cytology. Cancer Cytopathol 2011;119:158-166.
7.
Fujii T, Saito M, Hasegawa T et al: Performance of p16INK4a/Ki-67 immunocytochemistry for identifying CIN2+ in atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesions specimens: a Japanese Gynecologic Oncology Group study. Int J Clin Oncol 2015;20:134-142.
8.
Ikenberg H, Bergeron CH, Schmidt D, et al: Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst 2013;105:1550-1557
9.
Ordi J, Sagasta A, Munmany M, et al: Usefulness of p16/Ki67 Immunostaining in the triage of women referred to colposcopy. Cancer Cytopathol 2014;35:122-127.
10.
Wentzensen N, Schwartz L, Zuna RE, et al: Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin Cancer Res 2012;18:4154-4162.
11.
Ziemke P, Griesser H: Indications for p16-/Ki-67-immuncytochemistry in cervical cytology (in German). Pathologe 2017;38:38-44.
12.
Singh M, Mockler D, Akalin A, et al: Immunocytochemical colocalization of p16(INK4a) and Ki-67 predicts CIN2/3 and AIS/adenocarcinoma: pilot studies. Cancer Cytopathol 2011;120:26-34.
13.
Solares C, Velasco J, Alvarez-Ruiz E, et al: Expression of p16/Ki-67 in ASC-US/LSIL or normal cytology with presence of oncogenic HPV DNA. Anticancer Res 2015;35:6291-6296.
14.
Vrdoljak-Mozetic D, Krasevic M, Versa Ostojic D, et al: HPV16 genotype, p16/Ki-67 dual staining and koilocytic morphology as potential predictors of the clinical outcome for cervical low-grade squamous intraepithelial lesions. Cytopathology 2015;26:10-18.
15.
Ziemke P, Marquardt K, Griesser H: Predictive value of the combined p16INK4a and Ki-67 immunocytochemistry in low-grade squamous intraepithelial lesions. Acta Cytol 2014;58:489-494.
17.
zur Hausen H: Papillomavirus and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-350.
18.
Scholzen T, Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182:311-322.
19.
Van Oijen MGCT, Medema RH, Slootweg PJ, Rijksen G: Positivity of the proliferation marker Ki-67 in noncycling cells. Am J Clin Pathol 1998;110:24-31.
20.
Bergeron C, Ikenberg H, Sideri M, et al: Prospective evaluation of p16/Ki-67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results. Cancer Cytopathol 2015;123:373-381.
21.
Possati-Resende JC, Fregnani JH, Kerr LM, et al: The accuracy of p16/Ki-67 and HPV test in the detection of CIN2/3 in women diagnosed with ASC-US or LSIL. PLoS One 2015;10:e0134445.
22.
Waldstrøm M, Christensen RK, Ørnskov D: Evaluation of p16INK4a/Ki-67 dual stain in comparison with an mRNA human papillomavirus test on liquid-based cytology samples with low-grad squamous intraepithelial lesion. Cancer Cytopathol 2013;121:136-145.
23.
Koo Y-J, Hahn H-S, Lee I-H, et al: Dual immunostaining of cervical cytology specimens with atypical squamous cells for p16/Ki-67 does not exclude the existence of a high-grade squamous intraepithelial lesion. Virchows Arch 2013;463:689-696.
24.
Uijterwaal MH, Witte BI, van Kemenade FJ, et al: Triaging borderline/mild dyskaryotic Pap cytology with p16/Ki-67 dual-stained cytology testing: cross-sectional and longitudinal outcome study. Br J Cancer 2014;110:1579-1586.
25.
Uijterwaal MH, Polman NJ, Witte BI, et al: Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data. Int J Cancer 2015;136:2361-2368.
26.
Wentzensen N, Fetterman B, Castle PE, et al: p16/Ki-67 dual stain cytology for detection of cervical precancer in HPV-positive women. J Natl Cancer Inst 2015;107:1-8.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.